Gokul Raj Kathamuthu
Overview
Explore the profile of Gokul Raj Kathamuthu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
120
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Carow B, Muliadi V, Skalen K, Yokota C, Kathamuthu G, Setiabudiawan T, et al.
Front Immunol
. 2024 Feb;
14:1332733.
PMID: 38385142
Tuberculosis (TB) and sarcoidosis are both granulomatous diseases. Here, we compared the immunological microenvironments of granulomas from TB and sarcoidosis patients using sequencing (ISS) transcriptomic analysis and multiplexed immunolabeling of...
2.
Kathamuthu G, Moideen K, Sridhar R, Baskaran D, Babu S
Trop Med Infect Dis
. 2023 Mar;
8(3).
PMID: 36977151
Pro-inflammatory cytokines are potent stimulators of inflammation and immunity and markers of infection severity and bacteriological burden in pulmonary tuberculosis (PTB). Interferons could have both host-protective and detrimental effects on...
3.
Kathamuthu G, Rajamanickam A, Sridhar R, Baskaran D, Babu S
Front Immunol
. 2022 Nov;
13:999614.
PMID: 36341407
Soil-transmitted helminth [mainly (Ss)] and tuberculous lymphadenitis (TBL) coinfection in humans is a significant public health problem. We have previously shown that TBL+Ss+ coinfection significantly alters diverse cytokine, matrix metalloproteinase,...
4.
Sampath P, Natarajan A, Moideen K, Kathamuthu G, Hissar S, Dhanapal M, et al.
Front Immunol
. 2022 Aug;
13:892701.
PMID: 35911760
The rampant increase in drug-resistant tuberculosis (TB) remains a major challenge not only for treatment management but also for diagnosis, as well as drug design and development. Drug-resistant mycobacteria affect...
5.
Kathamuthu G, Bhavani P, Singh M, Saini J, Aggarwal A, Ansari M, et al.
Front Pharmacol
. 2022 Aug;
13:896551.
PMID: 35910352
High-dose rifampicin (HDR) is now undergoing clinical trials to improve the efficacy of anti-tuberculosis treatment (ATT). However, the influence of HDR in the modulation of different cytokines, chemokines/growth factors, microbial...
6.
Kathamuthu G, Sridhar R, Baskaran D, Babu S
PLoS One
. 2022 May;
17(5):e0269109.
PMID: 35617254
Lymph node culture-positive tuberculosis (LNTB+) is associated with increased mycobacterial antigen-induced pro-inflammatory cytokine production compared to LN culture-negative tuberculosis (LNTB-). However, the frequencies of CD4+, CD8+ T cells and NK...
7.
Kathamuthu G, Kumar N, Moideen K, Menon P, Babu S
J Immunol Res
. 2022 Mar;
2022:2422790.
PMID: 35242883
Natural killer (NK) and invariant NKT (iNKT) cells are unique innate lymphocytes that coordinate diverse immune responses and display antimycobacterial potential. However, the role of NK and iNKT cells expressing...
8.
Kathamuthu G, Kumar N, Moideen K, Dolla C, Kumaran P, Babu S
Pathogens
. 2022 Jan;
11(1).
PMID: 35056035
Mucosal-associated invariant T (MAIT) cells are innate like, and play a major role in restricting disease caused by (Mtb) disease before the activation of antigen-specific T cells. Additionally, the potential...
9.
Kathamuthu G, Moideen K, Sridhar R, Baskaran D, Babu S
Tuberculosis (Edinb)
. 2021 Dec;
132:102161.
PMID: 34891038
Adipocytokines are the major secretory products of adipose tissue and potential markers of metabolism and inflammation. However, their association in host immune response against tuberculous lymphadenitis (TBL) disease is not...
10.
Kathamuthu G, Kumar N, Moideen K, Menon P, Babu S
Front Cell Infect Microbiol
. 2021 Nov;
11:756854.
PMID: 34765568
Antigen-specific gamma-delta (γδ) T cells are important in exhibiting anti-mycobacterial immunity, but their role in latent tuberculosis (LTB) with diabetes mellitus (DM) or pre-DM (PDM) and non-DM comorbidities have not...